Jessica Teh

Jessica Teh, PhD, is a Senior Research Investigator at Arvinas, with expertise in Oncology Translational Science. Since April 2020, Jessica has led the pre-clinical development of Vepdegestrant (ARV-471) and has contributed to drug combination strategies while characterizing mechanisms of resistance, presenting three first-author posters at AACR 2023 and SABCS 2024. Previously, Jessica worked as an Institute Research Scientist at MD Anderson Cancer Center, leading a program on the KRAS pathway in cancer therapy, and as a Research Instructor at Thomas Jefferson University, where Jessica published significant findings on tumor immune interactions and metabolic responses in melanoma. Earlier research experience includes a Postdoctoral Fellowship and Graduate Studies at Rutgers University, as well as roles in technology transfer at UMDNJ. Jessica holds a Ph.D. in Cell and Developmental Biology from Rutgers University and a Bachelor's degree in Biotechnology from Penn State University.